Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
CPT: Pharmacometrics & Systems Pharmacology
|
July 31, 2015
Evaluating the Use of Linear Mixed-Effect Models for Inference of the Concentration-QTc Slope Estimate as a Surrogate for a Biological QTc Model
Y Huh, M M Hutmacher
Journal of Pharmacokinetics and Pharmacodynamics
|
July 27, 2001
Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test
K G Kowalski, M M Hutmacher
Statistics in Medicine
|
January 3, 2001
Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study
K G Kowalski, M M Hutmacher
Journal of Pharmacokinetics and Pharmacodynamics
|
September 20, 2012
Modeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI database
K Ito, M M Hutmacher, B W Corrigan
Clinical Pharmacology and Therapeutics
|
September 21, 2007
Modeling and simulation to support dose selection and clinical development of SC-75416, a selective COX-2 inhibitor for the treatment of acute and chronic pain
K G Kowalski, S Olson, A E Remmers, et al.
Clinical Pharmacology and Therapeutics
|
November 26, 2010
Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapine
S Chapel, M M Hutmacher, H Bockbrader, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 21, 2016
Population Exposure-Response Modeling of Naloxegol in Patients With Noncancer-Related Pain and Opioid-Induced Constipation
N Al-Huniti, J C Nielsen, M M Hutmacher, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
March 21, 2017
Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight
M M Hutmacher, K Papp, S Krishnaswami, et al.
Clinical Pharmacology and Therapeutics
|
November 19, 2016
Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib
M Lamba, M M Hutmacher, D E Furst, et al.
Clinical Pharmacology and Therapeutics
|
May 25, 2007
Model-based drug development
R L Lalonde, K G Kowalski, M M Hutmacher, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
CPT: Pharmacometrics & Systems Pharmacology
|
July 31, 2015
Evaluating the Use of Linear Mixed-Effect Models for Inference of the Concentration-QTc Slope Estimate as a Surrogate for a Biological QTc Model
Y Huh, M M Hutmacher
Journal of Pharmacokinetics and Pharmacodynamics
|
July 27, 2001
Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test
K G Kowalski, M M Hutmacher
Statistics in Medicine
|
January 3, 2001
Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study
K G Kowalski, M M Hutmacher
Journal of Pharmacokinetics and Pharmacodynamics
|
September 20, 2012
Modeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI database
K Ito, M M Hutmacher, B W Corrigan
Clinical Pharmacology and Therapeutics
|
September 21, 2007
Modeling and simulation to support dose selection and clinical development of SC-75416, a selective COX-2 inhibitor for the treatment of acute and chronic pain
K G Kowalski, S Olson, A E Remmers, et al.
Clinical Pharmacology and Therapeutics
|
November 26, 2010
Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapine
S Chapel, M M Hutmacher, H Bockbrader, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 21, 2016
Population Exposure-Response Modeling of Naloxegol in Patients With Noncancer-Related Pain and Opioid-Induced Constipation
N Al-Huniti, J C Nielsen, M M Hutmacher, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
March 21, 2017
Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight
M M Hutmacher, K Papp, S Krishnaswami, et al.
Clinical Pharmacology and Therapeutics
|
November 19, 2016
Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib
M Lamba, M M Hutmacher, D E Furst, et al.
Clinical Pharmacology and Therapeutics
|
May 25, 2007
Model-based drug development
R L Lalonde, K G Kowalski, M M Hutmacher, et al.
Page
of 1